Cancer Vaccines

Melanoma DNA Vaccine Trial Initiated

Published in Vaccine Weekly, August 10th, 1998

Vical Inc., San Diego, California, announced the initiation of a Phase I/II clinical trial to study the safety and potential efficacy of an experimental DNA vaccine for patients with metastatic melanoma.

The trial is being sponsored by the U.S. National Cancer Institute (NCI) under the direction of Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery.

The experimental vaccine contains a gene which may cause cells at the injection site to produce a modified gp100 melanoma antigen. The antigen is expected to trigger an immune response against melanoma tumor cells. In earlier studies, Rosenberg tested a vaccine using peptides (portions of the modified...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1998-08-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry